Tafalgie therapeutics team’s

5 Founders

Eric Schettini

President

Stephane Gaillard 

General Manager

Aziz Moqrich 

Chief Scientific Officer

Olivier Blin

President of the
Executive Committee

Laurent Labatut

Chairman on the board

The Scientific Committee

The Scientific Committee, chaired by Aziz Moqrich, is a collegial advisory body and does not constitute a management body. Its mission is to advise the Chairman and other senior managers of the company in defining and implementing the company’s strategic orientations, to ensure the quality, legitimacy and consistency of its research and development activities and to monitor developments in science.

John Levine

Neuroscientist

Prof. Levine’s study represents the point where « placebo biology » was born.

Jean-Louis Kraus

Professor Emeritus at the University of Aix Marseille and former Professor at McGill University Montreal Canada

Through his experience, Prof. Kraus has developed great networks during his career marked by commercial successes.

Alain Eschalier

Professor Emeritus at the University of Aix Marseille and former Professor at McGill University Montreal Canada

Prof. Eschalier is developing his research on the preclinical and clinical pharmacology of analgesics and the pathophysiology of chronic pain.

Laurent Labatut – Chairman on the board

THE PIPELINE

Discover the key milestones in the progress of the Tafalgie project

Eric Schettini

President

Stephane Gaillard

General Manager

Aziz Moqrich

CSO

After a PhD in neuroscience at Marseille, he became one of the specialists of the peripheral nervous system during his stay in the laboratory of the Pr Ardem Patapoutian in San Diego.

He came back to France in 2005, to build his own team, at the IBDM laboratory, focused on the identification of new molecular markers of sensory neurons.

Several projects led to publications in major international journals (Nature, Cell Reports, Science).
He is the chairman of the scientific council committee.

Olivier Blin

President of the Executive Committee

Professor of clinical pharmacology (AMU), past Visiting Prof at Imperial College (London), Olivier joined the company in 2022.

He has a large experience in drug development (past Head of Unit Physician at GSK, global early CNS drug development), public affairs (past member of the Board of the French Minister of Health) and regulatory affairs (past member of the Clinical Trial Committee at French Drug Agency) as well as Public-Private Partnerships (past member of IMI scientific committee in Bruxelles).

Laurent Labatut

Chairman on the board

Graduated from HEC then from Insead, he has held strategic positions in marketing, finance and general management (Danone, Ricard, Groupe Gascogne).

Notably, he was the CEO of the DRT group, one of the world leaders in phytochemistry (1,500 employees, turnover of 550 million euros).

He has a global vision of the world of chemistry and innovation as a business leader.